Abstract:To the Editor: A 74-year-old man was admitted to the First-Aid department because of persistent fever (391C), vomiting, and mucous-hemorrhagic diarrhea. The patient had no remarkable recent medical history except for hepatitis C infection. He was a pensioner, lived alone in Western Sicily (Italy), had no pets and frequently ate homemade foods as fresh and frozen meat (beef and pork steaks, chickens). Physical examination was normal except for a right subcostal painless or slightly tender hepatomegaly. Leukocyte count and serodiagnosis (Vidal-Wright) were normal. Ultrasound examination of the abdomen revealed a suspect hepatic abscess (2 3 cm) in the VII hepatic segment. Electrocardiography and chest radiography were normal. Empiric intravenous chemotherapy with piperacillin plus tazobactam (4g plus 0.500 g twice/day) was initiated. The following day the patient was still febrile (391C) and started derangement and delirium and slight stiff neck. Prednisolone (2mg/kg) and a dose of intravenous immunoglobulin (2 g/kg) were administered. On day 3 the patient was transferred to a neurologic department where acyclovir was added. Two blood cultures and lumbar puncture were negative. Over the following 3 days the patient’s condition improved slowly except for a slight clouding of consciousness and remittent fever (38, 51C to 391C). The patient was transferred to our department on day 5. He presented continuous fever (39.51C), coma (I degree), periodic apnea crisis and intermittent tremor. Neurologic examination showed paresis on the right side; deep tendon reflexes were brisk in the lower extremities and bilateral Babinski reflexes were positive. Blood and stool cultures were performed twice and antiedematous therapy was initiated. Anti-Yersinia antibody (IgA) was positive (1/800). Stool and abscesses cultures (assessed by liver puncture) were repeatedly positive for Yersinia enterocolitica infection; antibiogram was performed. PCR detected Y. enterocolitica (biotype 0:3) in blood. Contrast-enhanced computed tomodensitometric scan showed intraparenchyma areas of hypodensity consistent with cerebrocortical infarcts. Magnetic resonance imaging confirmed multiple peritrigonal and periventricular microabscesses in white matter. The patient was treated with ciprofloxacin (200mg q12h IV) for 10 days and his condition gradually improved and he was transferred to Rehabilitation Unit after 3 weeks. Y. enterocolitica as a collection of organisms is widespread in nature and terrestrial and aquatic ecosystems may become contaminated. The usual route of acquisition of Y. enterocolitica is through ingestion of food (meat, milk, etc) or water contaminated with the bacterium; as most of the contaminated food associated with outbreaks have cycled through refrigeration temperature which favors the growth of Y. enterocolitica, it must undergo a temperature adaptation in the human host before the initiation of an infection process. Y. enterocolitica withstands freezing very well and may survive for prolonged periods in frozen foods; in fact has been isolated even in frozen seafood; it shows elevated heat resistance in liquids. After ingestion, virulent plasmid-containing Y. enterocolitica attaches and invades M cells overlying Peyer patches by first binding to, and traversing, the mucus layer pathing mucosal epithelial cells. Clinically, Y. enterocolitica is primarily a gastrointestinal tract pathogen but it can induce extraintestinal spread under appropriate host (in relation to the age, immunologic status, and comorbidity). Some authors hypothesized immunologic involvement in acute and chronic neurologic disease during yersiniosis, but very little is known about possible neurologic manifestations associated with Y. enterocolitica infection. Our patient was a habitual eater of homemade foods as fresh and frozen meat. He presented a chronic Hepatitis C virus infection and this infection is associated with some immune system alterations and elevated levels of cytokine proinflammatory; has been reported that tumor necrosis factor-a, interleukin-2, and interleukin-6 can favor Yersinia infection. What remains remarkable in our case is the initial missed diagnosis of pyogenic liver and cerebral infection that led to unjustified steroid and antiviral therapy. Even though the patient’s leukocyte count and serodiagnosis were normal, the US signs of parenchimale abscesses should have initiated a thorough search for an unusual infective cause. Y. enterocolitica is primed to establish enteric tract pathology or to cause systemic disease in the appropriate host setting and physicians should consider this infection in their diagnostic proceeding and in routine testing of stool specimens.

Septicemia, hepatic abscess, and encephalitis due to Yersinia enterocolitica.

Packaged delivery of CRISPR-Cas9 ribonucleoproteins accelerates genome editing

Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing

Gene Editing by Extracellular Vesicles

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing

Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9

Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Nano-vectors for CRISPR/Cas9-mediated genome editing

Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics

Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA

Lipid, Inorganic, Polymer, and DNA Based Nanocarriers for Delivery of CRISPR/Cas9 System

[Reevaluation of spinal anesthesia in elderly people--an evaluation of circulatory changes].

Gene editing by ferrying of CRISPR/Cas ribonucleoprotein complexes in enveloped virus-derived particles

Key Considerations in Designing CRISPR/Cas9-carrying Nanoparticles for Therapeutic Genome Editing.

Key Considerations In Designing Crispr/Cas9-Carrying Nanoparticles For Therapeutic Genome Editing

Stochastic Packaging of Cas Proteins into Exosomes